Startseite>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>TH287 hydrochloride

TH287 hydrochloride

Katalog-Nr.GC37775

TH287-Hydrochlorid ist ein potenter und selektiver Inhibitor von MTH1 mit einem IC50-Wert von 0,8 nM. TH287-Hydrochlorid ist hochselektiv gegenÜber MTH1, ohne relevante Hemmung von MTH2, NUDT5, NUDT12, NUDT14, NUDT16, dCTPase, dUTPase und ITPA bei 100 μM. TH287-Hydrochlorid kÖnnte als Chemotherapeutikum fÜr die Krebsforschung dienen.

Products are for research use only. Not for human use. We do not sell to patients.

TH287 hydrochloride Chemische Struktur

Cas No.: 1638211-05-8

Größe Preis Lagerbestand Menge
5mg
70,00 $
Auf Lager
10mg
95,00 $
Auf Lager
50mg
376,00 $
Auf Lager
100mg
603,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TH287 hydrochloride is a potent inhibitor of MTH1 (NUDT1) with an IC50 value of 0.8 nM, less potent for MTH2, NUDT5, NUDT12, NUDT14, and NUDT16.IC50 value: 0.8 nM [1]Target: MTH1 inhibitorTH287 is considered a new target for cancer therapy. TH287 is highly selective towards MTH1, with no relevant inhibition of other members of the nudix protein family. TH287 has been shown to selectively kill a variety of cancer cell lines, but is rapidly metablized, so not as useful for in vivo studies.

[1]. Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21.

Bewertungen

Review for TH287 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TH287 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.